ATRA (STOCKS)
Atara Biotherapeutics, Inc
$5.150000
+0.260000 (+5.32%)
Prev close: $4.890000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Anhco Nguyen
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $42.08M
- Employees
- 38
- P/E (TTM)
- 2.00
- P/B (TTM)
- -0.98
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
5
Buy
2
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.25 | $-0.17 | -0.0752 | -43.02% |
|
Sep 2025 (Q3)
|
$-0.32 | $-0.88 | +0.5572 | +63.52% |
|
Jun 2025 (Q2)
|
$0.19 | $-0.47 | +0.6592 | +140.49% |
|
Mar 2025 (Q1)
|
$3.50 | $-2.02 | +5.5193 | +273.33% |
Financial Statements
| Revenues | $120.77M |
| Benefits Costs and Expenses | $88.05M |
| Costs And Expenses | $84.91M |
| Operating Expenses | $84.91M |
| Depreciation and Amortization | $2.12M |
| Research and Development | $37.45M |
| Other Operating Expenses | $45.35M |
| Operating Income/Loss | $35.86M |
| Income/Loss From Continuing Operations After Tax | $32.69M |
| Income/Loss From Continuing Operations Before Tax | $32.72M |
| Income Tax Expense/Benefit | $31.00K |
| Income Tax Expense/Benefit, Current | $31.00K |
| Income Tax Expense/Benefit, Deferred | $0.00 |
| Interest Expense, Operating | $3.79M |
| Net Income/Loss | $32.69M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $32.69M |
| Net Income/Loss Available To Common Stockholders, Basic | $32.69M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $2.61 |
| Diluted Earnings Per Share | $2.57 |
| Basic Average Shares | 12,544,000 |
| Diluted Average Shares | 12,718,000 |
| Assets | $20.24M |
| Current Assets | $12.21M |
| Inventory | $0.00 |
| Noncurrent Assets | $8.02M |
| Fixed Assets | $73.00K |
| Other Non-current Assets | $7.95M |
| Liabilities | $58.74M |
| Current Liabilities | $14.92M |
| Accounts Payable | $127.00K |
| Wages | $1.27M |
| Other Current Liabilities | $13.52M |
| Noncurrent Liabilities | $43.82M |
| Equity | -$38.50M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$38.50M |
| Liabilities And Equity | $20.24M |
| Net Cash Flow From Operating Activities | -$50.94M |
| Net Cash Flow From Operating Activities, Continuing | -$50.94M |
| Net Cash Flow From Investing Activities | $18.15M |
| Net Cash Flow From Investing Activities, Continuing | $18.15M |
| Net Cash Flow From Financing Activities | $16.10M |
| Net Cash Flow From Financing Activities, Continuing | $16.10M |
| Net Cash Flow | -$16.69M |
| Net Cash Flow, Continuing | -$16.69M |
| Comprehensive Income/Loss | $32.68M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $32.68M |
| Other Comprehensive Income/Loss | -$7.00K |